Metaba

Executive Summary

Metaba is a preclinical biopharmaceutical company leveraging a novel metabolomic and oxysterol-based platform to develop first-in-class antimicrobial therapies, initially targeting tuberculosis and other drug-resistant bacterial infections. Founded in 2021 and headquartered in San Francisco, the company operates through strategic collaborations with research institutions and pharmaceutical partners. Despite being at an early stage, Metaba's approach addresses a critical unmet need in the face of rising antimicrobial resistance. The company's platform enables the discovery of novel compounds that modulate host-pathogen interactions, potentially offering differentiated mechanisms of action. However, as a private, preclinical entity, Metaba faces significant technical and regulatory risks, and its valuation and funding history are undisclosed. The success of its pipeline hinges on advancing lead candidates through preclinical studies and securing sufficient capital to support IND-enabling activities. If successful, Metaba could become a key player in the infectious disease space, but near-term milestones remain uncertain.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing Round50% success
• Q2 2027Preclinical Proof-of-Concept Data for Lead TB Candidate40% success
• 2027Strategic Partnership or Licensing Deal35% success